argenx to Acquire Forte Biosciences for $2.2 Billion

Belgian biotechnology company argenx has signed an agreement to acquire Forte Biosciences in a deal valued at $2.2 billion. The acquisition is seen as part of argenx's strategy to expand its immunology portfolio. Under the terms of the agreement, argenx will purchase Forte Biosciences' shares for cash. Forte Biosciences is known for its innovative treatment candidates, particularly for autoimmune diseases, including a drug targeting skin conditions. This move by argenx reflects the company's goal to strengthen its R&D pipeline and enhance its competitive advantage in the market. The acquisition is expected to close in the first quarter of 2024. This is not investment advice.